| Literature DB >> 30204299 |
Kayo Kaneko1, Hiroshi Yatsuya1,2, Yuanying Li2, Mayu Uemura1, Chifa Chiang1, Yoshihisa Hirakawa1, Atsuhiko Ota2, Koji Tamakoshi3, Atsuko Aoyama1.
Abstract
AIMS/Entities:
Keywords: Alanine aminotransferase; Gamma-glutamyl transferase; Type 2 diabetes mellitus
Mesh:
Substances:
Year: 2018 PMID: 30204299 PMCID: PMC6497584 DOI: 10.1111/jdi.12930
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Baseline characteristics of the participants according to gamma‐glutamyl transferase and alanine aminotransferase levels, Aichi cohort study 2002, Japan
| Gamma‐glutamyl transferase (IU/L) |
| Alanine aminotransferase (IU/L) |
| |||||
|---|---|---|---|---|---|---|---|---|
| TI (8–27) | T2 (28–48) | T3 (49–1,121) | T1 (5–18) | T2 (19–27) | T3 (28–294) | |||
| ( | ( | ( | ( | ( | ( | |||
| Age (years) | 47.0 ± 7.3 | 48.5 ± 7.2 | 49.0 ± 6.5 | <0.01 | 48.5 ± 7.2 | 48.5 ± 7.0 | 47.5 ± 6.9 | <0.01 |
| Family history of diabetes (yes) | 124 (13.1) | 128 (14.8) | 120 (12.5) | 0.30 | 129 (13.1) | 99 (11.8) | 144 (15.2) | 0.10 |
| Regular physical activity (yes) | 207 (21.8) | 174 (20.2) | 200 (20.8) | 0.70 | 223 (22.7) | 174 (20.7) | 184 (19.4) | 0.20 |
| Current smoker (yes) | 285 (30.0) | 296 (34.3) | 403 (41.8) | <0.01 | 347 (35.3) | 285 (33.8) | 352 (37.1) | 0.36 |
| Alcohol intake (g/day) | 9.1 ± 16.2 | 14.9 ± 18.9 | 26.8 ± 26.0 | <0.01 | 16.4 ± 21.6 | 17.1 ± 22.0 | 17.7 ± 22.9 | 0.48 |
| <20 g/day | 817 (86.0) | 627 (72.7) | 474 (49.2) | <0.01 | 695 (70.7) | 589 (70.0) | 634 (66.7) | 0.14 |
| ≥20 g/day | 133 (14.0) | 235 (27.3) | 489 (50.8) | 288 (29.3) | 253 (30.0) | 316 (33.3) | ||
| Fasting blood glucose (mg/dL) | 91.6 ± 9.2 | 93.3 ± 8.8 | 95.1 ± 9.9 | <0.01 | 92.4 ± 9.4 | 93.6 ± 9.5 | 94.2 ± 9.4 | <0.01 |
| <100 mg/dL | 797 (83.9) | 681 (79.0) | 689 (71.5) | <0.01 | 810 (82.4) | 643 (76.4) | 714 (75.2) | <0.05 |
| 100–109 mg/dL | 112 (11.8) | 139 (16.1) | 189 (19.6) | 123 (12.5) | 150 (17.8) | 167 (17.6) | ||
| ≥110 mg/dL | 41 (4.3) | 42 (4.9) | 85 (8.8) | 50 (5.1) | 49 (5.8) | 69 (7.3) | ||
| Body mass index (kg/m2) | 22.2 (22.1–22.4) | 23.3 (23.1–23.4) | 23.7 (23.5–23.9) | <0.01 | 22.1 (22.0–22.3) | 23.0 (22.9–23.2) | 24.1 (23.9–24.2) | <0.01 |
| Triglycerides (mg/dL) | 94.9 (92.0–97.9) | 114.4 (110.5–118.5) | 145.9 (140.9–151.2) | <0.01 | 95.5 (92.5–98.6) | 116.1 (112.2–120.3) | 144.5 (139.4–149.7) | <0.01 |
| HDL‐c (mg/dL) | 55.1 (54.2–56.0) | 53.8 (52.9–54.8) | 54.9 (54.0–55.8) | 0.12 | 57.6 (56.7–58.6) | 54.2 (53.2–55.1) | 52.0 (51.2–52.8) | <0.01 |
| Total cholesterol (mg/dL) | 199.1 (197.2–201.1) | 207.8 (205.6–209.9) | 214.7 (212.5–216.9) | <0.01 | 199.8 (197.8–201.8) | 207.6 (205.5–209.7) | 214.5 (212.3–216.8) | <0.01 |
| Fasting insulin (μU/mL) | 5.6 (5.4–5.9) | 6.4 (6.1–6.6) | 7.1 (6.8–7.4) | <0.01 | 5.1 (4.9–5.3) | 6.2 (6.0–6.5) | 8.1 (7.7–8.5) | <0.01 |
| GGT (IU/L) | 19.7 (19.4–20.0) | 36.1 (35.7–36.5) | 86.4 (83.7–89.2) | <0.01 | 27.0 (26.1–27.9) | 38.1 (36.6–39.6) | 61.4 (58.7–64.3) | <0.01 |
| ALT (IU/L) | 17.3 (16.9–17.7) | 23.3 (22.7–24.0) | 31.8 (30.7–32.8) | <0.01 | 14.0 (13.8–14.2) | 22.4 (22.2–22.6) | 41.6 (40.7–42.6) | <0.01 |
Data are reported in mean ± standard deviation or number (%), unless otherwise specified. P‐values are from analysis of variance for continuous variables, and the χ2‐test for categorical variables. †Geometric mean and the 95% confidence interval. ALT, alanine aminotransferase; GGT, gamma‐glutamyl transferase; HDL‐c, high‐density lipoprotein cholesterol; T, tertile.
Crude hazard ratios and the 95% confidence intervals for the incidence of type 2 diabetes mellitus according to potential confounding variables, Aichi cohort study 2002–2015, Japan
| Crude HR (95% CI) | ||
|---|---|---|
| Age (years) | Per 1 year | 1.0 (1.0–1.1) |
| Family history of diabetes (yes) | 1.9 (1.4–2.5) | |
| Regular physical activity (yes) | 0.8 (0.6–1.1) | |
| Current smoking status (yes) | 1.5 (1.2–2.0) | |
| Alcohol intake (g/day) | Per 1 g/day | 1.0 (1.0–1.0) |
| Ln‐body mass index (kg/m2) | Per 1 SD | 1.4 (1.3–1.6) |
| Ln‐triglycerides (mg/dL) | Per 1 SD | 1.4 (1.3–1.6) |
| Ln‐HDL‐c (mg/dL) | Per 1 SD | 0.7 (0.7–0.8) |
| Ln‐total cholesterol (mg/dL) | Per 1 SD | 1.1 (0.9–1.2) |
| Fasting blood glucose | ||
| <100 mg/dL | REF | |
| 100–109 mg/dL | 3.2 (2.4–4.2) | |
| ≥110 mg/dL | 6.8 (5.0–9.3) | |
| Ln‐fasting insulin (μU/mL) | Per 1 SD | 1.4 (1.3–1.6) |
Total sample n = 2,775. Standard deviation (SD) for logarithmically transformed (Ln)(body mass index) = 0.1; SD for Ln(triglycerides) = 0.6; SD for Ln(high‐density lipoprotein cholesterol) = 0.3; SD for Ln(total cholesterol) = 0.2; SD for Ln(fasting insulin) = 0.7. HDL‐c, high‐density lipoprotein cholesterol; REF indicates reference.
Crude incidence rates, multivariable‐adjusted hazard ratios and the 95% confidence intervals for the incidence of type 2 diabetes mellitus according to tertiles of gamma‐glutamyl transferase or alanine aminotransferase, Aichi cohort study 2002–2015, Japan
| Gamma‐glutamyl transferase (IU/L) | Continuous HR per 1 SD | Alanine aminotransferase (IU/L) | Continuous HR per 1 SD | |||||
|---|---|---|---|---|---|---|---|---|
| TI (8–27) | T2 (28–48) | T3 (49–1,121) | T1 (5–18) | T2 (19–27) | T3 (28–294) | |||
| ( | ( | ( | ( | ( | ( | |||
| No. incidents | 59 | 71 | 146 | 67 | 71 | 138 | ||
| Person‐years | 9,691 | 8,325 | 9,025 | 9,764 | 8,234 | 9,043 | ||
| Crude incidence rate | 6.1 | 8.5 | 16.2 | 6.9 | 8.6 | 15.3 | ||
| HR 1 | REF | 1.1 (0.8–1.5) | 2.0 (1.4–2.8) | 1.4 (1.2–1.6) | REF | 1.1 (0.8–1.6) | 1.7 (1.2–2.3) | 1.4 (1.2–1.5) |
| HR 2 | 1.0 (0.7–1.4) | 1.4 (1.0–2.1) | 1.1 (0.9–1.3) | 1.0 (0.7–1.4) | 1.3 (0.9–1.8) | 1.2 (1.1–1.4) | ||
Hazard ratio (HR) 1: adjusted for age, family history of diabetes (yes/no), regular physical activity (yes/no), current, smoking status (yes/no), alcohol consumption (g/day), logarithmically transformed (Ln) body mass index (kg/m2), Ln triglycerides, Ln high‐density lipoprotein cholesterol and Ln total cholesterol. HR 2: adjusted for same covariates as HR 1 and Ln fasting insulin, fasting blood glucose as categories (<100, 100–109 and ≥110) and Ln gamma‐glutamyl transferase or Ln alanine aminotransferase (mutually adjusted). Standard deviation for Ln(gamma‐glutamyl transferase) = 0.7; standard deviation for Ln(alanine aminotransferase) = 0.5. REF, reference; T, tertile.
Association of categories of gamma‐glutamyl transferase, alanine aminotransferase and their combination with type 2 diabetes mellitus incidence stratified by drinking status, obesity and triglycerides, Aichi cohort study 2002–2015, Japan
| Gamma‐glutamyl transferase (IU/L) | Alanine aminotransferase (IU/L) | Combination of gamma‐glutamyl transferase and alanine aminotransferase | |||||
|---|---|---|---|---|---|---|---|
| Low (T1 + T2) (8–48) | High (T3) (49–1,121) | Low (T1 + T2) (5–27) | High (T3) (28–294) | Both low | Either high | Both high | |
| All participants | |||||||
| ( | ( | ( | ( | ( | ( | ( | |
| No. incidents | 130 | 146 | 138 | 138 | 89 | 90 | 97 |
| Person‐years | 18,016 | 9,025 | 17,998 | 9,043 | 1,4174 | 7,665 | 5,201 |
| Crude incidence rate | 7.2 | 16.2 | 7.7 | 15.3 | 6.3 | 11.7 | 18.7 |
| HR 1 | REF | 1.9 (1.4–2.4) | REF | 1.6 (1.2–2.1) | REF | 1.6 (1.2–2.1) | 2.3 (1.7–3.2) |
| HR 2 | 1.4 (1.1–1.0) | 1.3 (1.0–1.7) | 1.4 (1.1–1.9) | 2.0 (1.5–2.8) | |||
| Drinking status | |||||||
| <20 g/day | ( | ( | ( | ( | ( | ( | ( |
| No. incidents | 108 | 75 | 85 | 98 | 69 | 55 | 59 |
| Person‐years | 14,475 | 4,432 | 12,890 | 6,018 | 11,218 | 4,928 | 2,761 |
| Crude incidence rate | 7.5 | 16.9 | 6.6 | 16.3 | 6.2 | 11.2 | 21.4 |
| HR 1 | REF | 1.9 (1.4 –2.5) | REF | 2.1 (1.5–2.9) | REF | 1.6 (1.1–2.3) | 2.8 (1.9–4.1) |
| HR 2 | 1.3 (0.9–1.8) | 1.7 (1.2–2.3) | 1.4 (0.9–2.1) | 2.4 (1.7–3.6) | |||
| ≥20 g/day | ( | ( | ( | ( | ( | ( | ( |
| No. incidents | 22 | 71 | 53 | 40 | 20 | 35 | 38 |
| Person‐years | 3,540 | 4,593 | 5,108 | 3,025 | 2,956 | 2,737 | 2,440 |
| Crude incidence rate | 6.2 | 15.5 | 10.4 | 13.2 | 6.8 | 12.8 | 15.6 |
| HR 1 | REF | 2.1 (1.2–3.4) | REF | 1.0 (0.6–1.5) | REF | 1.6 (0.9–2.8) | 1.7 (0.9–3.0) |
| HR 2 | 1.9 (1.1–3.3) | 0.7 (0.5–1.3) | 1.4 (0.8–2.4) | 1.6 (0.9–2.9) | |||
| Body mass index | |||||||
| <25 kg/m2 | ( | ( | ( | ( | ( | ( | ( |
| No. incidents | 93 | 80 | 104 | 69 | 69 | 59 | 45 |
| Person‐years | 14,886 | 6,375 | 15,332 | 5,929 | 12,257 | 5703 | 3,300 |
| Crude incidence rate | 6.2 | 12.5 | 6.8 | 11.6 | 5.63 | 10.3 | 13.6 |
| HR 1 | REF | 1.9 (1.3–2.6) | REF | 1.6 (1.2–2.2) | REF | 1.6 (1.2–2.3) | 2.2 (1.5–3.4) |
| HR 2 | 1.5 (1.1–2.2) | 1.3 (0.9–1.8) | 1.5 (1.0–2.2) | 2.0 (1.3–3.0) | |||
| ≥25 kg/m2 | ( | ( | ( | ( | ( | ( | ( |
| No. incidents | 37 | 66 | 34 | 69 | 20 | 31 | 52 |
| Person‐years | 3,130 | 2,650 | 2,666 | 3113.7 | 1,917 | 1,966 | 1,901 |
| Crude incidence rate | 11.8 | 24.9 | 12.8 | 22.2 | 10.4 | 15.8 | 27.4 |
| HR 1 | REF | 1.9 (1.2–2.9) | REF | 1.4 (1.0–2.0) | REF | 1.4 (0.8–2.5) | 2.3 (1.3–3.9) |
| HR 2 | 1.3 (0.8–2.1) | 1.2 (0.8–1.8) | 1.3 (0.7–2.3) | 2.0 (1.1–3.4) | |||
| Triglyceride | |||||||
| <150 mg/dL | ( | ( | ( | ( | ( | ( | ( |
| No. incidents | 90 | 51 | 91 | 50 | 64 | 53 | 24 |
| Person‐years | 13,894 | 4,941 | 13,876 | 4,959 | 11,374 | 5,022 | 2439 |
| Crude incidence rate | ,6.5 | 10.3 | 6.6 | 10.1 | 5.6 | 10.6 | 9.8 |
| HR 1 | REF | 1.4 (1.0–2.0) | REF | 1.4 (1.0–2.0) | REF | 1.7 (1.2–2.5) | 1.5 (0.9–2.5) |
| HR 2 | 1.2 (0.8–1.7) | 1.2 (0.8–1.8) | 1.5 (1.0–2.1) | 1.5 (0.9–2.4) | |||
| ≥150 mg/dL | ( | ( | ( | ( | ( | ( | ( |
| No. incidents | 40 | 95 | 47 | 88 | 25 | 37 | 73 |
| Person‐years | 4,122 | 4,084 | 4,122 | 4,084 | 2,800 | 2,643 | 2,763 |
| Crude incidence rate | 9.7 | 23.3 | 11.4 | 21.6 | 8.9 | 14.0 | 26.4 |
| HR 1 | REF | 2.4 (1.6–3.6) | REF | 1.8 (1.3–2.6) | REF | 1.5 (0.9–2.5) | 2.9 (1.8–4.6) |
| HR 2 | 1.7 (1.1–2.6) | 1.4 (0.9–2.1) | 1.4 (0.8–2.3) | 2.5 (1.5–4.0) | |||
HR 1: adjusted for age, family history of diabetes (yes/no), regular physical activity (yes/no), current, smoking status (yes/no), alcohol consumption (g/day), logarithmically transformed (Ln) body mass index (kg/m2), Ln triglycerides, Ln high‐density lipoprotein cholesterol and Ln total cholesterol. HR 2: adjusted for the same covariates as HR 1 and Ln fasting insulin, fasting blood glucose as categories (<100, 100–109 and ≥110), and Ln gamma‐glutamyl transferase or alanine aminotransferase (mutually adjusted), except relevant strata variables. REF, reference; T, tertile.
Incremental predictive value of gamma‐glutamyl transferase or/and alanine aminotransferase for type 2 diabetes mellitus incidence at 10 years, Aichi cohort study 2002–2015, Japan
| Prediction model | C‐statistic (95% CI) | IDI (95% CI) |
| NRI (95% CI) |
|
|---|---|---|---|---|---|
| Base model | 0.747 (0.717–0.778) | REF | <0.05 | REF | <0.05 |
| Base model + Ln‐GGT | 0.754 (0.724–0.784) | 0.007 (0.001–0.018) | 0.130 (0.055–0.198) | ||
| Base model | 0.747 (0.715–0.779) | REF | <0.05 | REF | <0.01 |
| Base model + Ln‐ALT | 0.754 (0.723–0.785) | 0.010 (0.002–0.022) | 0.130 (0.051–0.212) | ||
| Base model | 0.747 (0.714–0.780) | REF | <0.01 | REF | <0.01 |
| Base model + Ln‐GGT +Ln‐ ALT + Int | 0.755 (0.723–0.788) | 0.012 (0.006–0.026) | 0.134 (0.056–0.207) | ||
| Base model + Ln‐GGT | 0.754 (0.723–0.785) | REF | <0.05 | REF | 0.060 |
| Base model + Ln‐GGT + Ln‐ ALT + Int | 0.755 (0.725–0.786) | 0.004 (0.000–0.015) | 0.135 (–0.004–0.186) | ||
| Base model + Ln‐ALT | 0.754 (0.724–0.785) | REF | 0.159 | REF | 0.106 |
| Base model + Ln‐ALT + Ln‐ GGT + Int | 0.755 (0.725–0.785) | 0.002 (0.000–0.010) | 0.096 (−0.039–0.156) |
Total sample n = 2,775. Base model included age, family history of diabetes (yes/no), regular physical activity (yes/no), current, smoking status (yes/no), alcohol consumption (g/day), body mass index (kg/m2), triglycerides, high‐density lipoprotein cholesterol, total cholesterol, fasting insulin, fasting blood glucose as categories (<100, 100–109 and ≥110). ALT, alanine aminotransferase, CI, confidence interval; GGT, gamma‐glutamyl transferase; Int, interaction for logarithmically transformed gamma‐glutamyl transferase × logarithmically transformed alanine aminotransferase; IDI, integrated discrimination improvement; Ln, logarithmically transformed; NRI, net reclassification improvement; REF, reference; T, tertile.